Literature DB >> 30411254

Prostaglandin E2/EP2 receptor signalling pathway promotes diabetic retinopathy in a rat model of diabetes.

Man Wang1, Yangningzhi Wang1, Tianhua Xie1, Pengfei Zhan1, Jian Zou2, Xiaowei Nie2,3, Jun Shao1, Miao Zhuang1, Chengye Tan1, Jianxin Tan2, Youai Dai2, Jie Sun2, Jiantao Li4, Yuehua Li4, Qian Shi5, Jing Leng6, Xiaolu Wang7,8, Yong Yao9.   

Abstract

AIMS/HYPOTHESIS: Diabetic retinopathy is a common microvascular complication of diabetes mellitus and is initiated by inflammation and apoptosis-associated retinal endothelial cell damage. Prostaglandin E2 (PGE2) has emerged as a critical regulator of these biological processes. We hypothesised that modulating PGE2 and its E-prostanoid receptor (EP2R) would prevent diabetes mellitus-induced inflammation and microvascular dysfunction.
METHODS: In a streptozotocin (STZ)-induced rat model of diabetes, rats received intravitreal injection of PGE2, butaprost (a PGE2/EP2R agonist) or AH6809 (an EP2R antagonist). Retinal histology, optical coherence tomography, ultrastructure of the retinal vascular and biochemical markers were assessed.
RESULTS: Intravitreal injection of PGE2 and butaprost significantly accelerated retinal vascular leakage, leucostasis and endothelial cell apoptosis in STZ-induced diabetic rats. This response was ameliorated in diabetic rats pre-treated with AH6809. In addition, pre-treatment of human retinal microvascular endothelial cells with AH6809 attenuated PGE2- and butaprost-induced activation of caspase 1, activation of the complex containing nucleotide-binding domain and leucine rich repeat containing family, pyrin domain containing 3 (NLRP3) and apoptosis-associated speck-like protein containing a C-terminal caspase-activation and recruitment domain (ASC), and activation of the EP2R-coupled cAMP/protein kinase A/cAMP response element-binding protein signalling pathway. CONCLUSIONS/
INTERPRETATION: The PGE2/EP2R signalling pathway is involved in STZ-induced diabetic retinopathy and could be considered as a potential target for diabetic retinopathy prevention and treatment.

Entities:  

Keywords:  Diabetic retinopathy; Endothelial cell; Inflammation; Microvascular disease; PGE2

Mesh:

Substances:

Year:  2018        PMID: 30411254     DOI: 10.1007/s00125-018-4755-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

Review 1.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  How leukocytes cross the vascular endothelium.

Authors:  Dietmar Vestweber
Journal:  Nat Rev Immunol       Date:  2015-10-16       Impact factor: 53.106

Review 3.  Endothelial cell apoptosis in angiogenesis and vessel regression.

Authors:  Emma C Watson; Zoe L Grant; Leigh Coultas
Journal:  Cell Mol Life Sci       Date:  2017-06-23       Impact factor: 9.261

4.  GSK-3β/CREB axis mediates IGF-1-induced ECM/adhesion molecule expression, cell cycle progression and monolayer permeability in retinal capillary endothelial cells: Implications for diabetic retinopathy.

Authors:  Takhellambam S Devi; Lalit P Singh; Ken-Ichi Hosoya; Tetsuya Terasaki
Journal:  Biochim Biophys Acta       Date:  2011-04-27

5.  Matrine suppresses AGE-induced HAEC injury by inhibiting ROS-mediated NRLP3 inflammasome activation.

Authors:  Yong Zhang; Xiaoqiang Yang; Chuan Qiu; Fei Liu; Peng Liu; Zhongwei Liu
Journal:  Eur J Pharmacol       Date:  2018-01-31       Impact factor: 4.432

6.  Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes.

Authors:  Jingfa Zhang; Yalan Wu; Ying Jin; Fei Ji; Stephen H Sinclair; Yan Luo; Guoxu Xu; Luo Lu; Wei Dai; Myron Yanoff; Weiye Li; Guo-Tong Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02       Impact factor: 4.799

Review 7.  The Double Roles of the Prostaglandin E2 EP2 Receptor in Intracerebral Hemorrhage.

Authors:  Xu Luo; Qiquan Zhu; Jie Zhang; Qin Huang; Zongyi Xie; Yuan Cheng
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

8.  CREB pathway links PGE2 signaling with macrophage polarization.

Authors:  Bing Luan; Young-Sil Yoon; John Le Lay; Klaus H Kaestner; Susan Hedrick; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

9.  Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.

Authors:  Surya P Ayalasomayajula; Uday B Kompella
Journal:  Eur J Pharmacol       Date:  2003-01-05       Impact factor: 4.432

10.  Hyperreflective intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: an in vivo study using spectral domain OCT.

Authors:  Stela Vujosevic; Silvia Bini; Giulia Midena; Marianna Berton; Elisabetta Pilotto; Edoardo Midena
Journal:  J Diabetes Res       Date:  2013-12-09       Impact factor: 4.011

View more
  13 in total

1.  LXA4 protects against blue-light induced retinal degeneration in human A2E-laden RPE cells and Balb-c mice.

Authors:  Tianhua Xie; Jiping Cai; Yong Yao; Chao Sun; Qian Yang; Meili Wu; Zifan Xu; Xiaodong Sun; Xiaolu Wang
Journal:  Ann Transl Med       Date:  2021-08

2.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

Review 3.  Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options.

Authors:  Josh O Wallsh; Ron P Gallemore
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

4.  The Anti-Inflammatory Effect of the β1-Adrenergic Receptor Antagonist Metoprolol on High Glucose Treated Human Microvascular Retinal Endothelial Cells.

Authors:  Giovanni Giurdanella; Anna Longo; Alfio Distefano; Melania Olivieri; Martina Cristaldi; Alessia Cosentino; Aleksandra Agafonova; Nunzia Caporarello; Gabriella Lupo; Carmelina Daniela Anfuso
Journal:  Cells       Date:  2021-12-24       Impact factor: 6.600

5.  Hyperglycemia-induced increasing of RELB/circ_0008590 in NF-κB pathway is repressed by miR-1243 in human retinal microvascular endothelial cells.

Authors:  Jun Shao; Jiping Cai; Yong Yao; Hui Zhu
Journal:  Ann Transl Med       Date:  2021-11

Review 6.  Recent Insights into the Role of Gut Microbiota in Diabetic Retinopathy.

Authors:  Jinghua Jiao; Honghua Yu; Litong Yao; Lihua Li; Xiaohong Yang; Lei Liu
Journal:  J Inflamm Res       Date:  2021-12-16

7.  Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice.

Authors:  Kumiko Suto; Daiju Fukuda; Masakazu Shinohara; Byambasuren Ganbaatar; Shusuke Yagi; Kenya Kusunose; Hirotsugu Yamada; Takeshi Soeki; Ken-Ichi Hirata; Masataka Sata
Journal:  J Atheroscler Thromb       Date:  2021-03-27       Impact factor: 4.928

Review 8.  The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders.

Authors:  Stefano Menini; Carla Iacobini; Martina Vitale; Giuseppe Pugliese
Journal:  Cells       Date:  2020-07-30       Impact factor: 6.600

Review 9.  Role of prostaglandin E2 in tissue repair and regeneration.

Authors:  Hui Cheng; Haoyan Huang; Zhikun Guo; Ying Chang; Zongjin Li
Journal:  Theranostics       Date:  2021-08-13       Impact factor: 11.556

Review 10.  Emerging Targets in Type 2 Diabetes and Diabetic Complications.

Authors:  Sevgican Demir; Peter P Nawroth; Stephan Herzig; Bilgen Ekim Üstünel
Journal:  Adv Sci (Weinh)       Date:  2021-07-28       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.